Investors sold shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on strength during trading on Wednesday. $571.61 million flowed into the stock on the tick-up and $655.46 million flowed out of the stock on the tick-down, for a money net flow of $83.85 million out of the stock. Of all companies tracked, Valeant Pharmaceuticals International had the 0th highest net out-flow for the day. Valeant Pharmaceuticals International traded up $3.40 for the day and closed at $30.00

A number of brokerages have commented on VRX. Morgan Stanley upgraded shares of Valeant Pharmaceuticals International from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $33.00 to $42.00 in a report on Wednesday. Zacks Investment Research upgraded shares of Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co. reiterated an “underperform” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday. Mizuho upgraded shares of Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and set a $25.00 price objective on the stock in a report on Monday. They noted that the move was a valuation call. Finally, TD Securities reiterated a “buy” rating and issued a $38.00 price objective on shares of Valeant Pharmaceuticals International in a report on Saturday, August 13th. Five analysts have rated the stock with a sell rating, sixteen have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $60.47.

The stock’s market capitalization is $10.43 billion. The company’s 50 day moving average is $23.35 and its 200 day moving average is $38.51.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the consensus estimate of $1.48 by $0.08. The business had revenue of $2.42 billion for the quarter, compared to analysts’ expectations of $2.47 billion. The company’s quarterly revenue was down 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.14 EPS. Analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current year.

In related news, CEO Joseph C. Papa acquired 202,000 shares of the stock in a transaction on Friday, June 10th. The stock was purchased at an average price of $24.48 per share, for a total transaction of $4,944,960.00. Following the transaction, the chief executive officer now owns 2,442,199 shares of the company’s stock, valued at approximately $59,785,031.52. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Argeris N. Karabelas acquired 4,000 shares of the stock in a transaction on Thursday, August 11th. The stock was bought at an average price of $24.65 per share, with a total value of $98,600.00. Following the transaction, the director now directly owns 20,726 shares in the company, valued at approximately $510,895.90. The disclosure for this purchase can be found here.

A number of large investors recently bought and sold shares of VRX. I.G. Investment Management LTD. boosted its stake in Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock valued at $135,033,000 after buying an additional 314,616 shares during the last quarter. Nicholas Co. Inc. WI boosted its stake in Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock valued at $161,310,000 after buying an additional 214,435 shares during the last quarter. Marshall Wace LLP boosted its stake in Valeant Pharmaceuticals International by 76.6% in the fourth quarter. Marshall Wace LLP now owns 65,386 shares of the specialty pharmaceutical company’s stock valued at $6,647,000 after buying an additional 28,365 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock valued at $28,900,000 after buying an additional 203,760 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock valued at $8,110,000 after buying an additional 2,500 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.